These 5-Amino-1MQ capsules contain the same molecule as the vial format — 5-amino-1-methylquinolinium, a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) — presented in a pre-portioned capsule format for laboratory research workflows. The compound is a quinolinium scaffold with a 5-amino group and an N1-methyl-derived cationic charge, typically supplied as the iodide salt (CAS 42464-96-0, C10H11IN2, 286.11 g/mol); the active cation corresponds to C10H11N2+ (PubChem CID 950107). NNMT catalyzes SAM-dependent methylation of nicotinamide to 1-methylnicotinamide, and 5-Amino-1MQ occupies the enzyme active site to slow this step in experimental systems.
The capsule format provides a fixed, uniform amount of 5-Amino-1MQ research material per unit, which some laboratories prefer for consistency across study arms. The identity and mechanism are identical to the powder/vial form; only the physical presentation differs. Supplied strictly as research material for laboratory use — Research Use Only.
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
As the same molecule as the vial format, 5-Amino-1MQ has been investigated in experimental and in-vitro settings as a selective NNMT inhibitor. Published studies report shifts in cellular methyl-donor and NAD+ handling with NNMT inhibition, and preclinical work has examined effects on adipocyte size, lipogenic signaling, and energy expenditure in rodent models of diet-induced obesity.
Further reports describe NNMT inhibition in skeletal-muscle contexts, including promotion of myoblast differentiation in cultured cells and effects on aged muscle stem cell regenerative capacity. The capsule format does not alter these research findings, which derive from preclinical, experimental, or in-vitro models and are provided for research context only.
5-Amino-1MQ arose from medicinal-chemistry programs developing cell-permeable NNMT inhibitors, with quinoline-derived scaffolds described in patent and peer-reviewed literature from the mid-2010s. Interest followed the identification of NNMT as a metabolic target in adipose tissue, and the compound is now widely used as a tool in metabolic and NAD+ research across multiple formats including capsules.
View compound profile on NIH PubChem →
Cited literature refers to laboratory and preclinical research. 5-Amino-1MQ Capsules is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
